INZY Insider Trading

Insider Trading Chart
Insider Trading History
Frequently Asked Questions
About

Insider Ownership Percentage: 11.19%

Insider Buying (Last 12 Months): $0.00

Insider Selling (Last 12 Months): $52,209.62

Inozyme Pharma Insider Trading History Chart

Inozyme Pharma Share Price & Price History

^$2.69

▼ -0.1 (-3.58%)

As of 11/21/2024 01:00 AM ET

Days: 30 | 90 | 365

This Bull Market Indicator called NVDA at $116

From WealthPress | Ad

Every now and again we find an investment idea so incredible we can’t help but share. And today is one of those rare days… Except, today we won't be giving you insight on any one particular stock… But rather, insight on a revolutionary new stock picking indicator… In fact, within the last year, this indicator has become famous for a multitude of reasons… But one of the biggest was because of the buy signal it issued on October 18th, 2022. In fact, on that very day, it said to buy NVDA at $116.37… Anyone who did would be sitting on a tremendously large return today… But even if you missed the original buy signal from October, this incredible indicator issued 11 other buy signals while Nvidia made its epic run…

All you have to do is follow this link here

Inozyme Pharma Insider Trading History

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
4/2/2024	Douglas A Treco	CEO	Sell	7,523	$6.94	$52,209.62	20,665
8/1/2023	Pivotal Bioventure Partners Fu	Director	Buy	833,333	$4.80	$3,999,998.40	2,923,110
5/11/2023	Robert Lorne Hopfner	Director	Buy	219,230	$6.48	$1,420,610.40	3,432,816
3/29/2023	Robert Lorne Hopfner	Director	Buy	344,592	$4.54	$1,564,447.68	3,213,586
3/27/2023	Robert Lorne Hopfner	Director	Buy	51,074	$3.70	$188,973.80	2,712,228
12/15/2022	Henric Bjorn Bjarke	COO	Buy	21,500	$1.39	$29,885.00	105,441
4/19/2022	Axel Bolte	CEO	Buy	67,750	$3.69	$249,997.50	258,575
4/19/2022	Henric Bjorn Bjarke	COO	Buy	27,100	$3.69	$99,999.00	80,626
4/19/2022	Longitude Capital Partners Iii	Major Shareholder	Buy	1,355,000	$3.69	$4,999,950.00	4,174,379
4/19/2022	Robert Lorne Hopfner	Director	Buy	1,070,000	$3.69	$3,948,300.00	2,661,154

2025 AI Stock Picks: 2 Hidden Gems Under $10/Share

From Darwin | Ad

The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.

👉[Click here to get your FREE report delivered instantly!]

SEC Filings (Institutional Ownership Changes) for Inozyme Pharma (NASDAQ:INZY)

88.30% of Inozyme Pharma stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

Inozyme Pharma Institutional Trading History

Reporting Date	Hedge Fund	Shares Held	Market Value	% of Portfolio	Quarterly Change in Shares	Ownership in Company
11/20/2024	Virtu Financial LLC	12,309	$64K	0.0%	N/A	0.019%
11/19/2024	Barclays PLC	76,730	$0.40M	0.0%	+261.4%	0.119%
11/16/2024	Geode Capital Management LLC	1,171,172	$6.13M	0.0%	+1.7%	1.823%
11/15/2024	Barclays PLC	76,730	$0.40M	0.0%	+261.4%	0.119%
11/15/2024	Jane Street Group LLC	49,460	$0.26M	0.0%	+7.5%	0.077%
11/15/2024	Wellington Management Group LLP	260,719	$1.36M	0.0%	+11.9%	0.406%
11/15/2024	Sphera Funds Management LTD.	1,191,140	$6.23M	1.0%	-18.6%	1.854%
11/15/2024	State Street Corp	1,050,420	$5.49M	0.0%	+5.0%	1.635%
11/15/2024	Readystate Asset Management LP	19,049	$100K	0.0%	N/A	0.030%
11/14/2024	Eventide Asset Management LLC	4,134,436	$21.62M	0.4%	+5.0%	6.436%
11/6/2024	OneDigital Investment Advisors LLC	20,000	$0.11M	0.0%	+51.5%	0.032%
11/5/2024	GSA Capital Partners LLP	35,402	$0.19M	0.0%	-13.5%	0.056%
10/23/2024	Values First Advisors Inc.	14,695	$77K	0.0%	-13.9%	0.024%
10/3/2024	SG Americas Securities LLC	15,457	$81K	0.0%	N/A	0.025%
9/16/2024	Cubist Systematic Strategies LLC	18,891	$84K	0.0%	N/A	0.031%
8/15/2024	Blue Owl Capital Holdings LP	1,120,027	$5M	1.4%	-11.8%	1.811%
8/15/2024	The Manufacturers Life Insurance Company	21,427	$96K	0.0%	+14.4%	0.035%
8/15/2024	Millennium Management LLC	1,787,947	$7.97M	0.0%	+154.1%	2.890%
8/15/2024	Deerfield Management Company L.P. Series C	11,591	$52K	0.0%	N/A	0.019%
8/15/2024	AQR Capital Management LLC	10,807	$48K	0.0%	-61.0%	0.017%
8/15/2024	Affinity Asset Advisors LLC	2,856,252	$12.74M	1.5%	+8.1%	4.618%
8/14/2024	Cubist Systematic Strategies LLC	18,891	$84K	0.0%	N/A	0.031%
8/14/2024	Samlyn Capital LLC	3,350,535	$14.94M	0.2%	+15.0%	5.417%
8/9/2024	Renaissance Technologies LLC	187,839	$0.84M	0.0%	+8.1%	0.304%
8/9/2024	Dimensional Fund Advisors LP	380,064	$1.70M	0.0%	+117.6%	0.614%
8/8/2024	Meeder Asset Management Inc.	15,210	$68K	0.0%	N/A	0.025%
8/8/2024	American Century Companies Inc.	57,100	$0.26M	0.0%	+11.0%	0.092%
8/1/2024	Rhumbline Advisers	77,004	$0.34M	0.0%	+22.0%	0.124%
7/26/2024	Bank of New York Mellon Corp	190,896	$0.85M	0.0%	+16.1%	0.309%
7/19/2024	Values First Advisors Inc.	17,067	$76K	0.0%	N/A	0.028%
5/16/2024	California State Teachers Retirement System	4,799	$37K	0.0%	-38.9%	0.008%
5/16/2024	Kennedy Capital Management LLC	437,657	$3.35M	0.1%	+52.2%	0.708%
5/15/2024	Affinity Asset Advisors LLC	2,642,519	$20.24M	2.5%	+40.1%	4.272%
5/10/2024	Vanguard Group Inc.	2,419,020	$18.53M	0.0%	+1.4%	3.911%
5/7/2024	SG Americas Securities LLC	13,926	$0.11M	0.0%	-34.4%	0.023%
5/3/2024	GSA Capital Partners LLP	131,098	$1M	0.1%	-21.5%	0.212%
2/20/2024	Eventide Asset Management LLC	3,179,837	$13.55M	0.2%	+1.8%	5.149%
2/15/2024	Octagon Capital Advisors LP	400,000	$1.70M	0.3%	-69.2%	0.648%
2/14/2024	Superstring Capital Management LP	123,944	$0.53M	0.4%	N/A	0.201%
2/13/2024	Affinity Asset Advisors LLC	1,885,802	$8.03M	1.5%	+36.7%	3.053%
1/19/2024	Denali Advisors LLC	22,000	$94K	0.0%	-17.6%	0.036%
1/18/2024	Values First Advisors Inc.	13,898	$59K	0.0%	N/A	0.023%
1/12/2024	SG Americas Securities LLC	21,236	$90K	0.0%	+46.9%	0.034%
11/15/2023	Rock Springs Capital Management LP	3,681,174	$15.46M	0.4%	+7.4%	5.960%
11/15/2023	Laurion Capital Management LP	677,329	$2.85M	0.0%	+170.5%	1.097%
11/15/2023	Adage Capital Partners GP L.L.C.	5,537,500	$23.26M	0.1%	+30.3%	8.966%
11/15/2023	Affinity Asset Advisors LLC	1,379,852	$5.80M	1.6%	+83.5%	2.234%
11/14/2023	Eventide Asset Management LLC	3,125,000	$13.13M	0.2%	N/A	5.060%
11/14/2023	Schonfeld Strategic Advisors LLC	311,880	$1.31M	0.0%	+346.8%	0.505%
11/14/2023	Pivotal bioVenture Partners Investment Advisor LLC	4,494,851	$18.88M	7.5%	+22.8%	7.278%
11/13/2023	CHI Advisors LLC	1,270,027	$5.33M	1.6%	+6.3%	2.056%
11/13/2023	FMR LLC	2,465,232	$10.35M	0.0%	+229.2%	3.992%
11/7/2023	New York State Common Retirement Fund	13,375	$56K	0.0%	-21.8%	0.022%
10/26/2023	Strs Ohio	9,900	$41K	0.0%	N/A	0.016%
10/13/2023	SG Americas Securities LLC	14,452	$61K	0.0%	N/A	0.023%
9/21/2023	Barclays PLC	10,205	$56K	0.0%	+62.7%	0.017%
8/22/2023	CHI Advisors LLC	1,195,027	$6.66M	2.0%	-11.0%	1.936%
8/15/2023	Sphera Funds Management LTD.	1,131,967	$6.31M	1.0%	-36.5%	1.834%
8/14/2023	Deep Track Capital LP	1,644,021	$9.16M	0.4%	-49.4%	2.663%
8/14/2023	Rock Springs Capital Management LP	3,428,084	$19.09M	0.5%	+6.6%	5.553%
8/11/2023	Pivotal bioVenture Partners Investment Advisor LLC	3,661,518	$20.40M	6.7%	+13.9%	5.932%
8/7/2023	Acadian Asset Management LLC	57,468	$0.32M	0.0%	N/A	0.124%
8/4/2023	Parallel Advisors LLC	15,427	$86K	0.0%	-22.3%	0.033%
8/4/2023	American International Group Inc.	16,292	$91K	0.0%	N/A	0.035%
7/18/2023	Denali Advisors LLC	26,700	$0.15M	0.1%	N/A	0.061%
5/15/2023	Affinity Asset Advisors LLC	751,796	$4.31M	1.4%	+50.4%	1.718%
5/11/2023	CHI Advisors LLC	1,342,191	$7.69M	2.0%	-39.1%	3.067%
5/11/2023	Knott David M Jr	160,000	$0.92M	0.4%	N/A	0.366%
5/1/2023	Virtu Financial LLC	46,995	$0.27M	0.0%	N/A	0.107%
2/10/2023	NEA Management Company LLC	2,437,689	$2.56M	0.1%	-0.3%	6.035%
11/14/2022	UBS Oconnor LLC	165,498	$0.44M	0.0%	-3.4%	0.412%
8/16/2022	Deerfield Management Company L.P. Series C	2,696,372	$12.86M	0.3%	+15.0%	6.724%
8/15/2022	Laurion Capital Management LP	271,800	$1.30M	0.0%	+2,618.0%	0.678%
8/15/2022	Pivotal bioVenture Partners Investment Advisor LLC	2,661,154	$12.69M	6.4%	+67.2%	6.637%
8/11/2022	Bioimpact Capital LLC	664,980	$3.17M	0.9%	+125.4%	1.658%
8/11/2022	Overbrook Management Corp	69,326	$0.33M	0.1%	+314.5%	0.173%
8/8/2022	Walleye Capital LLC	101,442	$0.48M	0.0%	N/A	0.253%
2/15/2022	Laurion Capital Management LP	13,390	$91K	0.0%	-81.1%	0.057%
2/15/2022	Adage Capital Partners GP L.L.C.	1,599,028	$10.91M	0.0%	+8.9%	6.757%
2/14/2022	Suvretta Capital Management LLC	1,013,216	$6.91M	0.1%	+2.7%	4.281%
2/11/2022	Bioimpact Capital LLC	302,615	$2.06M	0.4%	-5.6%	1.279%
2/8/2022	Northern Trust Corp	120,762	$0.82M	0.0%	+4.0%	0.510%
2/2/2022	New York State Common Retirement Fund	3,834	$26K	0.0%	-63.3%	0.016%
11/16/2021	Suvretta Capital Management LLC	986,400	$11.43M	0.2%	+170.1%	4.168%
11/16/2021	Wellington Management Group LLP	364,600	$4.23M	0.0%	-50.0%	1.541%
11/16/2021	Laurion Capital Management LP	70,700	$0.82M	0.0%	N/A	0.299%
11/16/2021	BioImpact Capital LLC	320,724	$3.72M	0.6%	N/A	1.355%
11/16/2021	CHI Advisors LLC	920,264	$10.67M	3.1%	-0.8%	3.889%
11/15/2021	Deerfield Management Company L.P. Series C	2,344,786	$27.18M	0.5%	+7.6%	9.910%
11/15/2021	Rock Springs Capital Management LP	850,015	$9.85M	0.2%	+1.2%	3.592%
11/15/2021	Marshall Wace LLP	33,408	$0.39M	0.0%	-16.9%	0.141%
11/15/2021	Caas Capital Management LP	135,398	$1.57M	0.0%	N/A	0.572%
11/12/2021	Geode Capital Management LLC	198,624	$2.30M	0.0%	+10.5%	0.839%
11/8/2021	Russell Investments Group Ltd.	115,516	$1.34M	0.0%	+4,518.8%	0.488%
11/2/2021	New York State Common Retirement Fund	10,453	$0.12M	0.0%	+18.8%	0.044%
11/1/2021	SG Americas Securities LLC	11,611	$0.14M	0.0%	N/A	0.049%
8/25/2021	Marshall Wace LLP	40,202	$0.69M	0.0%	-22.4%	0.170%
8/17/2021	Millennium Management LLC	61,313	$1.05M	0.0%	-58.9%	0.259%
8/17/2021	Burrage Capital Management LLC	242,517	$4.13M	4.1%	+43.1%	1.025%
8/17/2021	Citadel Advisors LLC	171,066	$2.92M	0.0%	-28.8%	0.723%

Data available starting January 2016

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Today's Range

Now: $2.69

$2.61

$2.80

50 Day Range

MA: $4.79

$2.79

$6.00

52 Week Range

Now: $2.69

$2.61

$7.80

Volume

371,356 shs

Average Volume

416,774 shs

Market Capitalization

$172.81 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.54

Who are the company insiders with the largest holdings of Inozyme Pharma?: Inozyme Pharma's top insider investors include:
Robert Lorne Hopfner (Director)
Pivotal Bioventure Partners Fu (Director)
Henric Bjorn Bjarke (COO)
Douglas A Treco (CEO)
Learn More about top insider investors at Inozyme Pharma.
Who are the major institutional investors of Inozyme Pharma?: Inozyme Pharma's top institutional investors include:
Eventide Asset Management LLC — 6.44%
Sphera Funds Management LTD. — 1.85%
Geode Capital Management LLC — 1.82%
State Street Corp — 1.64%
Wellington Management Group LLP — 0.41%
Barclays PLC — 0.12%
Learn More about top institutional investors of Inozyme Pharma stock.
Which institutional investors are selling Inozyme Pharma stock?: Within the previous quarter, INZY stock was sold by these institutional investors:
Sphera Funds Management LTD.
GSA Capital Partners LLP
Values First Advisors Inc.
Which institutional investors are buying Inozyme Pharma stock?: Within the previous quarter, INZY stock was bought by institutional investors including:
Eventide Asset Management LLC
Barclays PLC
Barclays PLC
State Street Corp
Wellington Management Group LLP
Geode Capital Management LLC
Readystate Asset Management LP
SG Americas Securities LLC
In the previous year, these company insiders have bought Inozyme Pharma stock:
Robert Lorne Hopfner (Director)
Pivotal Bioventure Partners Fu (Director)
Henric Bjorn Bjarke (COO)
Learn More investors buying Inozyme Pharma stock.